Neurizon Therapeutics
June 23, 2026
Theater 4
Type: Company Presentation
Focus Area:
Brain Health
Neurizon Therapeutics is a clinical-stage biotechnology company developing disease-modifying therapies that target the underlying pathology of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Huntington’s disease and Frontotemporal Dementia.
Our lead program, NUZ-001, is a first-in-class oral therapy designed to address core mechanisms of neurodegeneration, including TDP-43 protein aggregation and impaired autophagy. Because TDP-43 pathology is present in more than 95% of ALS cases and implicated across multiple neurodegenerative conditions, NUZ-001 has the potential to serve as a multi-indication platform therapy.
NUZ-001 has completed Phase 1 and OLE studies, demonstrating a favourable safety and tolerability profile with encouraging efficacy signals. The program has started patient dosing in the Phase 2/3 HEALEY ALS Platform Trial, an established registration-level framework offering an accelerated and capital-efficient path to potential approval.
Company HQ City:
Melbourne
Company HQ State:
Victoria
Company HQ Country:
Australia
Year Founded:
2000
Lead Product in Development:
NUZ-001
CEO
Michael Thurn
Development Phase of Lead Product
Phase II
Exchange
ASX
Ticker
NUZ
When you expect your next catalyst update?
July 2026 (Full Enrollment), April 2027 (Topline Results)
What is your next catalyst (value inflection) update?
Full enrollment of Phase 2/3 Healey ALS Platform Trial (H2 2026) and topline results release (H1 2027)
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}